my community channel

Register to store your favourite programmes, receive schedule alerts, sign up for factsheets, participate in forums and much more...

What's On

Sat 22nd Nov 2008
	20:00	Charge
	21:00	The Street Where You Live
	21:25	Volunteer Films 2008
	21:30	New Consumer TV
	22:00	UN Westminster & N.Y. Film Fest.

full schedule

Home

Your Charity Space

Squiffy's Space

This item viewed 607 times

Other entries by Squiffy:

Results 1 - 5 of 190

About Squiffy

Webmaster and Discussion Board Administrator for the Multiple Sclerosis Resource Centre. http...

more...

ATL/TV1102 reduces disease activity in multiple sclerosis patients

Create new blog

Teva Pharmaceutical Industries Ltd. and Antisense Therapeutics Ltd. announced that anti-sense drug, ATL/TV1102, significantly reduced disease activity in patients with relapsing-remitting multiple sclerosis.

The companies noted that their Phase IIa study met its primary endpoint showing a significant reduction by 54.4% in cumulative number of new active lesions in patients taking ATL/TV1102, compared to placebo. In general, ATL/TV1102 was well tolerated..........

For the full report please go to MSRC: MS Research News : Drugs : Further Possible MS Drugs and Treatments

Comments

There are no comments currently....

You must login to leave comments...

Last Updated ( Monday, 30 June 2008 )

back to Your Charity Space

donate

send us feedback